Skip to main content
      RT @synovialjoints: Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)&lt

      Dr. Antoni Chan synovialjoints

      4 years ago
      Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11
      RT @DrMiniDey: Do RA autoantibodies incr the risk of MACE?

      In study of ~2000 pts, ⬆️ concentrations of RA-related a

      Mrinalini Dey DrMiniDey

      4 years ago
      Do RA autoantibodies incr the risk of MACE? In study of ~2000 pts, ⬆️ concentrations of RA-related autoantibodies assoc. w/ MACE and/or CVD-mortality. Autoantibodies may therefore directly contribute to excess CVD risk in RA... Abs#0269 #ACR21 @RheumNow https://t.co/ju3YCRonJt https://t.co/UcOMsYxVMP
      RT @Janetbirdope: Which pt has more MIs post elective surgery? #ACR21 @RheumNow abst#0128

      Janet Pope Janetbirdope

      4 years ago
      Which pt has more MIs post elective surgery? #ACR21 @RheumNow abst#0128
      RT @AurelieRheumo: Finally a way to improve Fatigue in RMDs? PLUS it is non pharmaceutical and remote⚡️! Cognitive B

      Aurelie Najm AurelieRheumo

      4 years ago
      Finally a way to improve Fatigue in RMDs? PLUS it is non pharmaceutical and remote⚡️! Cognitive Behavioural approaches and Personalised Exercise Interventions: ⬇️ Fatigue Severity and Impact ⬆️ Sleep at 1yr in a multiarm RCT. #OP0462 @RheumNow #ACR2021 https://t.co/5buGCYb5Ut https://t.co/4Wz2VmcL3x
      RT @KDAO2011: Winning Image Competition: Rheum Dz in Patients of Color: Dermatomyositis #ACR21 @rheumnow https://t.co/OF

      TheDaoIndex KDAO2011

      4 years ago
      Winning Image Competition: Rheum Dz in Patients of Color: Dermatomyositis #ACR21 @rheumnow https://t.co/OFRDDgQqas
      RT @KDAO2011: Erosive polyarticular chronic tophaceous gout

      Regional Winner of East Asia and Pacific
      Image Competition

      TheDaoIndex KDAO2011

      4 years ago
      Erosive polyarticular chronic tophaceous gout Regional Winner of East Asia and Pacific Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/1wrNAhjsw6
      RT @_Castillo_Pedro: SLE patients with +aPL was associated with:
      ➡️Nephritis
      ➡️Discoid rash
      ➡️Serositis
      ➡ï

      Pedro Castillo _Castillo_Pedro

      4 years ago
      SLE patients with +aPL was associated with: ➡️Nephritis ➡️Discoid rash ➡️Serositis ➡️Neurologic disorder Consider aPL and LAC status in patients w/these manifestations and whether anticoagulation/antiplatelets may be needed #ACR21 Abst#0077 @RheumNow
      RT @KDAO2011: Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation

      Regional Winner of Europe &amp; Ce

      TheDaoIndex KDAO2011

      4 years ago
      Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation Regional Winner of Europe & Central Asia Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/vxayxgINa8
      RT @KDAO2011: Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans

      Regional Winner of Latin America a

      TheDaoIndex KDAO2011

      4 years ago
      Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans Regional Winner of Latin America and Caribbean Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/4oAXIClwsm
      RT @ericdeinmd: #ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
      ▶️150

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
      RT @Janetbirdope: #SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matche

      Janet Pope Janetbirdope

      4 years ago
      #SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matched controls. Esp driven by comorbidities. Should we add ASA post op in SLE pts with CV risks? #ACR21 #abst0128 @RheumNow https://t.co/COdbDxFgBQ
      RT @uptoTate: Rare co-existence of FMF &amp; axSpA significantly lowered age of axSpA symptom onset. Radiographic change

      Dr. Rachel Tate uptoTate

      4 years ago

      Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

      RT @KDAO2011: KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
      👉phase 3 DBRPCT

      TheDaoIndex KDAO2011

      4 years ago
      KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
      RT @AkhilSoodMD: Abs 0463 #ACR21 @RheumNow
      Park &amp; colleagues compared treatment persistence across abatacept, TNFi,

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
      RT @ericdeinmd: #ACR21 Abst#0454
      Lupus nephritis mortality from 1999-2019
      ⭐️-27% age-standardized mortality rate in

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0454 Lupus nephritis mortality from 1999-2019 ⭐️-27% age-standardized mortality rate in LN death, though increased trend in last 5 yrs! ▶️ Afr-American 38% of deaths, though 12% of population (RR ~4.5), ⬆️mortality with urbanization https://t.co/fjeGXtItvD @RheumNow https://t.co/cE3t6lq8zi
      ×